Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

However, analysts from Cantor Fitzgerald, Oppenheimer, and JPMorgan were among those to reiterate their buy-equivalent ratings on Regeneron (NASDAQ:REGN) despite the trial setback. “We do still ...

The S&P 500 slipped less than 0.1% on Friday, May 30, 2025, as President Trump rekindled his tough rhetoric on China and a ...

The disappointing guidance spurred a downgrade at JPMorgan. - Regeneron Pharmaceuticals (REGN) shares slump after Wells Fargo Securities cut the recommendation on Regeneron Pharmaceuticals Inc. to ...

Regeneron Pharmaceuticals (REGN ... declined as the maker of contact lenses cut its full-year organic growth outlook and JPMorgan downgraded the stock and lowered its price target on concerns about ...

JPMorgan Reiterates 2025 Net Interest Income Forecast. Wall Street Awaits Any Word on Dimon Succession Plans. The bank says it is â positioned to deliver strong returns' in the face of ...

Fintel reports that on May 30, 2025, Wells Fargo downgraded their outlook for Regeneron Pharmaceuticals (BMV:REGN) from Overweight to Equal-Weight. Jpmorgan Chase holds 5,658K shares representing ...

Dollar General ( DG) was the best-performing stock in the S&P 500 after the discount retailer beat profit and sales estimates ...